The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Abstract
Background Studies have reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the magnitude of the risk and whether this risk changes with the severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CVD events.Methods We systematically searched PubMed, Scopus, and Web of Science from database inception to July 1, 2021, to identify eligible observational studies examining the risk of incident CVD events amongst adult (age ≥18 years) individuals with and without NAFLD and in which NAFLD was diagnosed by imaging, International Classification of Diseases codes, or liver biopsy. The primary outcomes were CVD death, non-fatal CVD events, or both. Data from selected studies were extracted, and meta-analysis was performed using random-effects models to obtain summary hazard ratios (HRs) with 95% CIs. The quality of the evidence was assessed with the Cochrane risk of bias tool. This study is registered on Open Science Framework, number osf.io/5z7gf.Findings We identified 36 longitudinal studies with aggregate data on 5 802 226 middle-aged individuals (mean age 53 years [SD 7]) and 99 668 incident cases of fatal and non-fatal CVD events over a median follow-up of 6·5 years (IQR 5·0-10·2). NAFLD was associated with a moderately increased risk of fatal or non-fatal CVD events (pooled random-effects HR 1·45, 95% CI 1·31-1·61; I 2=86·18%). This risk markedly increased across the severity of NAFLD, especially the stage of fibrosis (pooled random-effects HR 2·50, 95% CI 1·68-3·72; I 2=73·84%). All risks were independent of age, sex, adiposity measures, diabetes, and other common cardiometabolic risk factors. Sensitivity analyses did not modify these results.Interpretation NAFLD is associated with an increased long-term risk of fatal or non-fatal CVD events. CVD risk is further increased with more advanced liver disease, especially with higher fibrosis stage. These results provide evidence that NAFLD might be an independent risk factor for CVD morbidity and mortality.Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, individuals with MASLD have a higher risk of non-fatal cardiovascular disease (HR 1.40), 25”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although some studies indicated a higher risk of cardiovascular disease-related mortality (HR 1.30), 25,26 others did not con fi rm this result in the general population, but only in those with biopsy-proven MASH 24 or other risk factors like T2D. 15”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhou, Y. J., Li, Y. Y., Nie, Y. Q., Huang, C., & Cao, C. Y. (2011) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00571.x · Cited by 80
RetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Self-citationNonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,251
Cited by
Sorted by citations
Items 301–400 of 691
Goldberg, D. T., Meir, A. Y., Tsaban, G., Rinott, E., Kaplan, A., Zelicha, H., Klöting, N., Ceglarek, U., Iserman, B., Shelef, I., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000867 · Cited by 8
From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status
Boccatonda, A., D’Ardes, D., Moronti, V., Santilli, J., Cipollone, A., Lessiani, G., Gregorio, N. D., Serra, C., Piscaglia, F., Ferri, C., et al. (2024) · Medicina · doi:10.3390/medicina60111781 · Cited by 8
Zhu, X., Yin, H., Han, J., Zhang, X., Han, Q., Sun, W., Liu, Y., Tao, W., Liu, X., Wang, G., et al. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s520688 · Cited by 8
Zinterl, I., Ittermann, T., Schipf, S., Groß, S., Anspieler, H., Kim, S., Ewert, R., Bülow, R., Kühn, J., Lerch, M. M., et al. (2022) · Liver International · doi:10.1111/liv.15162 · Cited by 8
Self-citationChen, X., Chen, Z., Jiang, L., Huang, J., Zhu, Y., & Lin, S. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.11.007 · Cited by 8
Fragkou, N., Vlachaki, E., Goulis, I., & Sinakos, E. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.671 · Cited by 8
Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease
Săsăran, M. O., Muntean, C., Lupu, A., & Lupu, V. V. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1336033 · Cited by 7
Ebrahimi, F., Ebrahimi, R., Hagström, H., Sundström, J., Sun, J., Bergman, D., Forss, A., & Ludvigsson, J. F. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.010912 · Cited by 7
Scores to predict steatotic liver disease – correlates and outcomes in older adults
Clayton‐Chubb, D., Commins, I., Roberts, S. K., Majeed, A., Woods, R. L., Ryan, J. L., Schneider, H. G., Lubel, J. S., Hodge, A. D., McNeil, J. J., et al. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00021-3 · Cited by 7
Lv, J., Yao, J., Zheng, L., Shao, J., Jin, J., Zheng, Q., Teng, J., Zhou, J., Cai, F., Huang, P., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01715-7 · Cited by 7
Zhang, H., Lin, F., Miao, M., Yu, C., & Guo, W. Y. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00951-y · Cited by 7
Cardiovascular risk in MASLD: What multiple lines of evidence reveal
Sattar, N. A., Dalakoti, M., Alazawi, W., & Aroda, V. R. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.02.015 · Cited by 7
Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 9
Self-citationPompili, E., Baldassarre, M., Iannone, G., Tedesco, G., Nardelli, S., Piano, S. S., Alessandria, C., Neri, S., Foschi, F. G., Levantesi, F., et al. (2024) · Liver International · doi:10.1111/liv.16020 · Cited by 7
Park, S. H., Park, J., Kim, H., Lee, J., Kwon, S. Y., Lee, Y., Kim, G., Jin, S., Hur, K. Y., & Kim, J. H. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03758-6 · Cited by 7
Byrne, C. D., & Targher, G. (2022) · Gut · doi:10.1136/gutjnl-2022-328316 · Cited by 7
Self-citationNon-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease
Beer, S., Babel, J., Neef, M., Blank, V., Wiegand, J., & Karlas, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286882 · Cited by 7
Lonardo, A., Beghé, B., & Fabbri, L. M. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.06 · Cited by 7
Li, X., Xiao, Y., Chen, X., Zhu, Y., Du, H., Shu, J. H., Yu, H., Ren, X., Zhang, F., Dang, J., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00204 · Cited by 6
Bae, J. C. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2340 · Cited by 6
Putri, R. R. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1675713 · Cited by 6
Zahid, M., Lal, A., Almas, A., & Parkash, O. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01353-4 · Cited by 6
Mantovani, A., Lombardi, R., Dalbeni, A., Morandin, R., Lando, M. G., Fiorio, V., Rolli, N., Forti, M. D., Messetti, D., Zoncapè, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70245 · Cited by 6
Self-citationZhang, Z., Lu, J., Chen, M., Dai, L., Xiang, Y., Liu, Z., Cao, Y., Sheng, W., Li, C., Song, D., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02784-3 · Cited by 6
Kim, D. Y., Zhang, H., Lee, J. S., Lee, H. W., Kim, B. K., Kim, B. K., Kim, S. U., Kim, D. Y., Ahn, S. H., Gee, H. Y., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101713 · Cited by 8
Feng, Q., Manousou, P., Izzi‐Engbeaya, C. N., Loomba, R. S., Thursz, M. R., & Woodward, M. (2025) · Liver International · doi:10.1111/liv.70485 · Cited by 7
Cao, Z., Chen, B., Zhou, J., Jin, J., Abramov, D., Chen, S., Huang, P., & Zhou, J. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101438 · Cited by 6
Küçükukur, M., & Binici, R. (2026) · Angiology · doi:10.1177/00033197261427829 · Cited by 6
Yang, X., & Peng, W. J. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261435033 · Cited by 6
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6
Wang, T.-J., Chen, M., Lin, Y., Chiu, W., Huang, T., & Weng, H. (2024) · BMC Public Health · doi:10.1186/s12889-024-17851-0 · Cited by 6
Kim, G., Yu, T. Y., Bae, J. C., Bae, J. C., Kang, M., & Kim, J. H. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101534 · Cited by 6
Dalal, N., Catalli, L., Miller, S. A., Madan, S. K., Tan, R., Agudelo, E. Z., & Brandman, D. (2024) · BMC Public Health · doi:10.1186/s12889-024-18865-4 · Cited by 6
Kaushal, K. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_458_24 · Cited by 6
Kang, M. K., Song, J. E., Kweon, Y. O., Tak, W. Y., Park, S. Y., Lee, Y. R., & Park, J. G. (2024) · Diagnostics · doi:10.3390/diagnostics14202305 · Cited by 6
Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors
Capinha, F., Carvalhana, S. C., & Cortez‐Pinto, H. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08912-4 · Cited by 6
Wu, W., Cheng, J., Hou, Z., Yan, Q., Wang, X., He, J., Zhu, Y., & Li, J. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01846-x · Cited by 7
Ichikawa, K., Miyoshi, T., Nakashima, M., Nishihara, T., Osawa, K., Miki, T., Toda, H., Yoshida, M., & Ito, H. (2022) · Heart and Vessels · doi:10.1007/s00380-022-02107-x · Cited by 6
Rivera‐Esteban, J., Pons, M., Planas, A., Manzano-Núñez, R., Hernández, C., Simó‐Servat, O., Bañeras, J., Soler, M. J., Serón, D., Boixadera, A., et al. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.11.001 · Cited by 6
Schreiner, A. D., & Sattar, N. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12124001 · Cited by 6
Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
Benlloch, S., Moncho, F., & Górriz, J. L. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.03.009 · Cited by 6
Inciardi, R. M., Merlo, M., Bellicini, M., Setti, M., Luca, A. D., Meo, N. D., Rondi, P., Pagnesi, M., Adamo, M., Lombardi, C., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.04.009 · Cited by 6
Self-citationOrsi, E., Solini, A., Bonora, E., Vitale, M., Garofolo, M., Fondelli, C., Trevisan, R., Vedovato, M., Cavalot, F. L., Laviola, L., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01942-8 · Cited by 7
Tan, J., Sun, W., Dong, X., He, J., Ali, A. M. M., Chen, M., Zhang, L., Wu, L., & Shao, K. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1574151 · Cited by 5
Bentanachs, R., Ramírez-Carrasco, P., Braster, B., Emmanouilidou, A., Mújica, E., Rodrigo‐Calvo, M. T., Rodrı́guez, C., Roglans, N., den Hoed, M., Laguna, J. C., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107860 · Cited by 5
Zhang, J., Feng, S., Xue, J., Zhou, C., Fu, S., Liu, P., He, Z., Gong, M., Feng, H., Zhou, S.-N., et al. (2025) · iLiver · doi:10.1016/j.iliver.2025.100181 · Cited by 5
Baratta, F., Cocomello, N., Carpino, G., Colantoni, A., Cammisotto, V., Bartimoccia, S., Castellani, V., Overi, D., Lucatelli, P., Ettorre, E., et al. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109540 · Cited by 5
Zhou, X., Chen, Q., Kim, S. U., Yip, T. C., Petta, S., Nakajima, A., Tsochatzis, E. A., Boursier, J., Bugianesi, E., Hagström, H., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.038 · Cited by 5
Self-citationManshi, Dash, D., & Koiri, R. K. (2026) · Endocrine · doi:10.1007/s12020-026-04561-3 · Cited by 6
Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting
Urias, E., & Chen, V. L. (2023) · Seminars in Liver Disease · doi:10.1055/a-2082-5203 · Cited by 5
Liver fibrosis is associated with an increased risk of non‐fatal myocardial infarction
Riccio, A., Mazzanti, C., Vero, L., Fiorentino, T. V., Succurro, E., Rubino, M., Massimino, M., Mannino, G. C., Sciacqua, A., Andreozzi, F., et al. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14061 · Cited by 5
Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV
Laguno, M., de Lazzari, E., Berrocal, L., Inciarte, A., Martínez‐Rebollar, M., de la Mora, L., Torres, B., Gonzalez‐Cordón, A., Chivite, I., Foncillas, A., et al. (2024) · HIV Medicine · doi:10.1111/hiv.13730 · Cited by 5
Kawanaka, M., Nishino, K., Kawada, M., Ishii, K., Tanikawa, T., Urata, N., Suehiro, M., Haruma, K., & Kawamoto, H. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4373-24 · Cited by 6
Li, Y., Geng, S., Yuan, H., Ge, J., Li, Q., Chen, X., Zhu, Y., Liu, Y., Guo, X., Wang, X., et al. (2024) · Journal of Global Health · doi:10.7189/jogh.14.04263 · Cited by 6
Ahmed, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061841 · Cited by 5
Glutathionylation and metabolic dysfunction-associated steatotic liver disease
Jiang, Z., Chen, L., & Dou, X. (2025) · Biochimie · doi:10.1016/j.biochi.2025.03.006 · Cited by 6
Zhang, Y., Zhang, X., Huang, C., & Zhu, L. (2025) · Biomedicines · doi:10.3390/biomedicines13040956 · Cited by 5
Mohammedsaeed, W. M., Malki, A. A., & Alsayed, S. M. (2025) · Saudi Medical Journal · doi:10.15537/smj.2025.46.5.20240901 · Cited by 5
Prevalence and outcomes of steatotic liver disease subtypes in older adults
Clayton‐Chubb, D., Majeed, A., Commins, I., Woods, R. L., Chan, A. T., Ryan, J. L., Neumann, F., Schneider, H. G., Tonkin, A., Nelson, M. R., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000756 · Cited by 5
Carresi, C., Cardamone, A., Musolino, V., Mollace, R., Tavernese, A., Coppoletta, A. R., Gliozzi, M., & Mollace, V. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118375 · Cited by 5
Association of NAFLD and Cardiovascular Events
Bhatia, M. K., Garg, A., Ali, J., Santos, A. D., Bhatia, M. K., Singh, B., Bassi, M., Broder, A., & Adler, D. G. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002232 · Cited by 5
Bocci, G., Orlandi, P., Manca, M. L., Rossi, C., Salvati, A., Brunetto, M. R., & Solini, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11205985 · Cited by 5
Käräjämäki, A. J., Hukkanen, J., & Ukkola, O. H. (2022) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000489 · Cited by 5
The Challenging Ethical Landscape of Non-alcoholic Fatty Liver Disease
Berry, P., & Kotha, S. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/21-00217 · Cited by 5
Esteatosis hepática metabólica y nefropatía diabética: una llamada a la acción
Benlloch, S., Moncho, F., & Górriz, J. L. (2023) · Nefrología · doi:10.1016/j.nefro.2023.08.005 · Cited by 5
Zhou, B., Xia, J.-L., Jiang, X., Ding, Y., & She, Q. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01569-6 · Cited by 5
Tuo, L., Yan, L., Liu, Y., & Yang, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1315046 · Cited by 5
Heerkens, L., Geleijnse, J. M., & van Duijnhoven, F. J. B. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03431-w · Cited by 5
Pan, L., Wang, L., Ma, H., & Ding, F. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16760 · Cited by 5
Sebastiani, G., Raggi, P., & Guaraldi, G. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.06.075 · Cited by 5
Sonaglioni, A., Cerini, F., Nicolosi, G. L., Lombardo, M., Rumi, M. G., & Viganò, M. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002375 · Cited by 5
Reinson, T., Patel, J., Mathews, M., Fountain, D., Buchanan, R. M., & Byrne, C. D. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00335 · Cited by 5
Self-citationNabeta, T., Myagmardorj, R., Hirasawa, K., Singh, G. K., van der Kley, F., de Weger, A., Knuuti, J. M., Bax, J. J., Marsan, N. A., & Delgado, V. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.09.023 · Cited by 5
Optimising the management of cardiovascular comorbidities in NAFLD patients: it’s time to (re-) act!
Kasper, P., Lang, S., Demir, M., & Steffen, H. (2022) · Gut · doi:10.1136/gutjnl-2021-326662 · Cited by 5
Byrne, C. D., & Dore, G. J. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.001 · Cited by 5
Self-citationThe Impact of Obesity on Diabetes Onset and Neovascularization in Mouse Models of Metabolic Stress
Venkata, S. P. M., Li, H., Xu, L., & Wang, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021214 · Cited by 4
Williams, D. M., Ali, J., Cragg, J., Ch’ng, C. L., Williams, N. W., Stephens, J. W., & Min, T. (2024) · Cureus · doi:10.7759/cureus.75993 · Cited by 4
de Jong, V., Theel, W. B., Cabezas, M. C., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101337 · Cited by 4
Laparoscopically confirmed endometriosis and the risk of incident NAFLD: a prospective cohort study
Huang, H., Liu, Z., Ruan, J., Fang, Z., & Xu, C. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01391-2 · Cited by 4
Hamadouche, M., Vilgrain, V., Hobeika, C., Castéra, L., Valla, D. C., Rautou, P., Matteini, F., Garteiser, P., BEERS, B. E. V., Corréas, J.-M., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11774-z · Cited by 4
Zhou, Q., Liu, P., Zhou, D., Zhang, Y., Li, Z., Li, Z., & Ma, X. (2025) · Medicine · doi:10.1097/md.0000000000043952 · Cited by 4
Diagnosis and management of metabolic dysfunction associated steatotic liver disease
Musso, G., Lassen, A., Banda, L., Maher, J. J., & Gambino, R. (2025) · BMJ · doi:10.1136/bmj-2025-084950 · Cited by 5
p16 Ink4a ‐Positive Hepatocytes Drive Liver Fibrosis Through Activation of LIFR Family Pathway
Nishikawa, K., Wang, T., Kawakami, S., Tanimoto, S., Yamaguchi, K., Kido, T., Kimura, M., Hishima, T., Okamura, Y. T., Omori, S., et al. (2026) · Advanced Science · doi:10.1002/advs.202510562 · Cited by 4
Cardiovascular-Kidney-Metabolic Syndrome: Development of an ICD-10-CM Coding Framework
ZHAO, M., Zhang, J., Wang, H., Xu, C., Li, J., Li, C., He, X., & Zheng, X. (2026) · JMIR Diabetes · doi:10.2196/91827 · Cited by 4
Filippatos, T. D., Katrapas, P., Tsiampalis, T., Chrysohoou, C. A., Barkas, F., Liberopoulos, E. N., Sfikakis, P. P., Tsioufis, C., Pitsavos, C. E., Panagiotakos, D. B., et al. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02056-9 · Cited by 4
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Kasper, P., Demir, M., & Steffen, H. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0059 · Cited by 4
Korpimäki, S., Rovio, S., Juonala, M., Hutri‐Kähönen, N., Lehtimäki, T. J., Laitinen, T. P., Tossavainen, P. H., Jokinen, E. V., Loo, B.-M., Männistö, S., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad418 · Cited by 4
Statin Prescribing Patterns in Patient-Centered Medical Home Patients With NAFLD
Cipriani, A. L. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89406 · Cited by 4
Lonardo, A. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00026 · Cited by 4
Ganesan, K., Xu, C., Liu, Q., Sui, Y., & Chen, J. (2023) · Cells · doi:10.3390/cells12182311 · Cited by 4
Feng, B., Li, F., Lan, Y., Wang, X., Chen, S., Yang, C., Yin, M., Cui, F., Wang, G., Zhou, D., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae546 · Cited by 4
Doustmohammadian, A., Amirkalali, B., de Courten, B. V., Esfandyari, S., Motamed, N., Maadi, M., Ajdarkosh, H., Gholizadeh, E., Chaibakhsh, S., & Zamani, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-70181-4 · Cited by 4
Risk of Serious Bacterial and Non‐Bacterial Infections in People With MASLD
Targher, G., Tilg, H., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70059 · Cited by 6
Self-citationToffoli, B., Comar, C., Grillo, A., Barbato, V., Vincis, E., Baldi, V., Berti, S., Volpato, T., Zorat, F., Crocè, L. S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073256 · Cited by 4
Wang, X.-Y., Lyu, Q., Zhang, Y., Su, Y., Zhao, H., Shen, H., & Xie, Y. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.129 · Cited by 4
Mohanty, A., Austad, K., Bosch, N. A., Long, M. T., Nolen‐Doerr, E., Walkey, A. J., Drainoni, M., Rizo, I. M., & Fantasia, K. L. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.014 · Cited by 4
Chew, N., Muthiah, M. D., & Sanyal, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00003-6 · Cited by 4
Pantelis, A. G. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.55 · Cited by 4
Why are there no strategies for NAFLD?
Byrne, C. D., Newsome, P. N., & Noureddin, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.009 · Cited by 4
Self-citationToke, N., Rathod, A. M., Phalak, P., & Patel, V. (2024) · Egyptian Liver Journal · doi:10.1186/s43066-024-00348-1 · Cited by 3
Metadata
- Authors
- Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G.
- Affiliations
- University of Verona (IT)
- Harvard University (US)
- Southampton General Hospital (GB)
- Corresponding author
- Targher, Giovanni
- ORCID
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 6
- Issue
- 11
- Pages
- 903-913
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W3201276384
- Cited by
- 674
- References
- 75
- Citations by year
- 2026: 160 · 2025: 151 · 2024: 141 · 2023: 122 · 2022: 95 · 2021: 4
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Funders
- National Institute for Health Research Southampton Biomedical Research Centre (IS-BRC-20004)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular mortality, cardiovascular events, liver fibrosis, disease severity, cardiometabolic risk factors, cardiovascular risk factors, middle-aged adults, NAFLD staging
- MeSH terms
- Cardiovascular Diseases, Humans, Risk Factors, Severity of Illness Index, Models, Statistical, Survival Analysis, Observational Studies as Topic, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
